Contineum Therapeutics Announces Pricing of Upsized $90M Public Offering

Gunderson Dettmer represented client Contineum Therapeutics, a clinical-stage biopharmaceutical company, in the pricing of an upsized underwritten public offering of 7,346,938 shares of its Class A common stock at a public offering price of $12.25 per share. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other estimated offering expenses payable by Contineum, are expected to be approximately $90.0 million.

Contineum is focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific clinical impairments for the treatment of neuroscience, inflammation and immunology indications with high unmet need.

Goldman Sachs & Co. LLC, Leerink Partners, Stifel, RBC Capital Markets and William Blair acted as joint book-running managers for the offering. Jones acted as manager for the offering.

The Gunderson deal team was led by Jeff Thacker and Ryan Gunderson and included Traci Biedermann, Jack Weykamp, and Lily Kim.

Companies
Contineum Therapeutics
Goldman Sachs & Co. 
Leerink Partners
Stifel
RBC Capital Markets
William Blair
Jones